Downregulation of SHIP-1 expression is implicated in chronic myeloid leukemia, Crohn’s Disease, T cell leukemia, SLE, ulcerative colitis and Systemic Lupus Erythematous, both in humans and mice [26,31], as well as in preclinical models of PC [11,12,35]. Here, INPP5D is linked to chronic myelogenous leukemia, BCR-ABL1 positive.